As of 30 Sep 2025, 58 institutional investors reported holding $547,434,225 in principal (par value) of BIOMARIN PHARMACEUTICAL INC - NOTE 1.250% 5/1.
| Period | Principal | Value | Change | Price (% of par) (Median) | Investors |
|---|---|---|---|---|---|
| 2025 Q4 | $10,000 | $959,589 | 9595.89% | 1 | |
| 2025 Q3 | $547,434,225 | $521,865,010 | +$30,701,081 | 95.0% | 58 |
| 2025 Q2 | $537,501,514 | $508,246,066 | +$82,026,221 | 94.13% | 66 |
| 2025 Q1 | $446,615,880 | $421,992,836 | -$3,972,778 | 94.39% | 63 |
| 2024 Q4 | $434,189,749 | $403,988,210 | +$16,729,848 | 92.8% | 71 |
| 2024 Q3 | $410,986,406 | $391,760,463 | -$44,062,310 | 95.06% | 61 |
| 2024 Q2 | $458,050,177 | $439,334,457 | -$26,395,056 | 95.72% | 58 |
| 2024 Q1 | $483,730,000 | $480,004,809 | +$12,046,434 | 99.1% | 57 |
| 2023 Q4 | $84,655,000 | $87,350,370 | 102.94% | 2 | |
| 2023 Q3 | $376,924,779 | $374,538,744 | +$15,073,603 | 99.09% | 47 |
| 2023 Q2 | $362,451,200 | $365,935,950 | +$30,176,333 | 100.86% | 47 |
| 2023 Q1 | $332,555,033 | $347,197,165 | +$77,647,985 | 104.3% | 44 |
| 2022 Q4 | $257,262,174 | $283,126,263 | +$42,290,479 | 107.69% | 44 |
| 2022 Q3 | $209,064,035 | $176,516,431 | -$102,635,053 | 99.48% | 36 |
| 2022 Q2 | $319,539,619 | $282,367,350 | -$9,899,667 | 99.38% | 34 |
| 2022 Q1 | $323,191,062 | $294,550,950 | +$129,663,104 | 100.14% | 28 |
| 2021 Q4 | $216,888,919 | $195,023,129 | -$31,376,459 | 104.22% | 32 |
| 2021 Q3 | $248,705,814 | $435,777,986 | +$2,612,174 | 100.08% | 26 |
| 2021 Q2 | $243,593,220 | $246,900,040 | +$246,897,255 | 100.45% | 28 |